OBJECTIVES: The French public health law of 9 August 2004 took this need into consideration and provided for the implementation of a quality of life improvement programme for those affected by chronic illnesses. Furthermore, the 87th of the 110 Public Health objectives is aimed at “Improving the quality of life of those suffering from osteoarthritis”  Describe what impact treating sufferers of osteoarthritis has on their quality of life. METHODS: Quality of life was also evaluated for subjects suffering from gonarthritis using the SF-12 score, which is an approved generic tool for determining the physical and mental state of health of populations. RESULTS:A total of 256 subjects suffering from gonarthritis were randomised into 2 groups: 127 randomised subjects were placed in the group treated with ACS Avian, and 129 randomised subjects in the group receiving the placebo. Upon inclusion, the PCS-12 scores were 36.43 and 36.64 for the group treated with ACS Avian and the group receiving the placebo respectively. The 2 groups were similar upon inclusion. After 6 months of treatment, the PCS-12 scores were 42.25 and 39.47 for the group treated with ACS Avian and the group receiving the placebo respectively. There was a statistically significant improvement in the physical dimension score of the group of patients treated with ACS Avian compared with that of the placebo group (p<0.05). CONCLUSIONS: These various studies confirm the sharp deterioration in the physical dimension of quality of life of patients with gonarthritis.  There was a statistically significant improvement in the physical dimension score of the group of patients treated with ACS Avian compared with that of the placebo group.This data confirms the pertinence of both the public health objective fixed by the health authorities, and the use of ACA Avian in the treatment of osteoarthritis.